MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GRZANNA, R.
Right arrow Articles by COYLE, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GRZANNA, R.
Right arrow Articles by COYLE, J. T.

Molecular Pharmacology, Vol 13, 956-964, Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics

Immunochemical Studies on the Turnover of Rat Serum Dopamine beta-Hydroxylase

R. GRZANNA 1 and J. T. COYLE 1

1 Departments of Pharmacology and Experimental Therapeutics and of Psychiatry and the Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Intravenous injection of homologous antiserum to rat dopamine beta-hydroxylase causes a rapid, dose-dependent reduction in the activity of the enzyme. The enzyme-neutralizing effect of the antiserum is 1000 times greater in vivo than in vitro. The injected antiserum does not affect dopamine beta-hydroxylase activity in peripheral adrenergic tissues. The kinetics of the rate of reappearance of dopamine beta-hydroxylase activity in serum after treatment with the antiserum have been calculated. The rate constant for the entrance of enzyme into the circulation is 2.8 units/ml/day, the first-order rate constant for the degradation of the serum enzyme is 0.166 day-1, and the half-life of serum dopamine beta-hydroxylase in the rat is 4.2 days.

Note:
ACKNOWLEDGMENTS We thank Dr. Manfred M. Mayer for helpful discussions, and acknowledge the excellent technical assistance of Robert Zaczek and the secretarial skills of Carol Kenyon and Vickie Rhodes.

Submitted on March 22, 1977
Accepted on May 13, 1977




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
M. J. Kreek, G. Bart, C. Lilly, K. S. Laforge, and D. A. Nielsen
Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments
Pharmacol. Rev., March 1, 2005; 57(1): 1 - 26.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics